The treatment by CUR technology of the CNS diseases that CUR addresses can result in serious cost savings to health care providers. Many patients that suffer from stroke damage, ALS symptoms and spinal cord injuries require intensive personal health care, with no likelihood of any meaningful recovery or abatement in care costs. If CUR can improve the patients condition in any way, then real cost savings can result. Moreover, CUR's paradigm shift in treating depression could also be groundbreaking and result in blockbuster status. Should CUR science be proven to arrest or reverse some of these conditions, then the SP will skyrocket to numbers that would be considered astronomical. In part for the above reasons, but also for the reason that there are no competitors for this type of treatment or these conditions. As an example, note that a major BP yesterday announced the cessation of its development of an ALS drug that did not prove to help any of its ALS patients. CUR is it for the foreseeable future and are so far advanced in its development than any of its competitors. While some see 3-5 or 8-10 within a year, I see the reasonable possibility of substantially more than that in 2-4 years. CUR's science can literally make dreams come true for its patients and its investors, imo.
I think that their depression drug has not gotten as much attention as it deserves, and it's one of the main reasons that I invested in the company. First quarter news from the Phase I NSI-189/MDD trial would be an added catalyst to the share price. I can understand how it can be dwarfed by the publicity and potential of their ALS treatment though.
I have told my risk-averse friends to invest a small portion of their $$$ in this company. Even a small amount of shares could be worth quite a bit if their pipeline proves successful.
I agree tuaca65, I'm particularly interested in NSI-189, even though ALS gets the most publicity. NSI-189, although described as an "anti-depression" treatment, could turn out to be (or some variation of it) a brain-injury or even Alzheimer's treatment, IMO. I like both of these, but it seems NSI-189 isn't getting much valuation here. But that could change in Q1 or Q2 of this year.
I agree, the upside is huge. NSI-566 is beginning to look like the only game in town now for ALS, with some efficacy/safety to show from the data, this could be an exciting year for CUR, with all possible use of multiple applications, and NS-189. The upside is potentially huge for all involved.
Just wondering when the next so called "Analyst" Report will come out trying to bash this company again. Seeking Alpha and Maxim I'm sure are in the works to try and bash this company when it gets around 1.50. What a joke they are.